Quintiles

PPD names CEO, puts acquisition rumors in question

Monday, September 26, 2011 08:02 AM

PPD has named a new CEO, a move that strikes some in the industry as a little strange in the face of rumors that the publicly traded CRO is close to selling itself to a private equity firm.

More... »

Eisai partners with SFJ in new outsourcing model

Friday, September 9, 2011 11:30 AM

Eisai has put the late-stage clinical development, as well as the associated funding, of a candidate compound for thyroid cancer in the hands of SFJ Pharma, wholly subsidiary of a US-based company that specializes in getting innovative drugs to market in Japan, according to PharmaTimes.

More... »

PPD rumored to be in exclusive acquisition talks with D.C.-based private equity firm the Carlyle Group

Monday, August 22, 2011 08:02 AM

While many in the upper echelon of private equity investors have been courting CRO PPD, for now all but one have been shooed away: Washington, D.C.-based Carlyle Group.

More... »

PPD denies CRO merger rumors, but stays mum on possibility of private equity takeover

Monday, July 25, 2011 08:00 AM

In the wake of last week’s Wall Street Journal report claiming PPD might be putting itself on the block, the top-tier CRO responded with a statement that it is not discussing mergers with other CROs. But what about private equity firms?

More... »

PPD shares rise on takeover rumors

Monday, July 18, 2011 01:51 PM

Shares of CRO Pharmaceutical Product Development (PPD) rose 16% to levels not touched in more than two-and-a-half years on Monday, a day after a Wall Street Journal report said the company was looking to sell itself, reported Reuters.

More... »

Survey: Biopharmaceutical industry needs innovation

Tuesday, July 12, 2011 12:12 PM

A new Economist Intelligence Unit survey sponsored by CRO Quintiles highlights the urgent need for biopharmaceutical industry innovation. The global survey comes as the biopharma sector reaches the patent cliff—this year and next, seven of the world’s 15 top-selling drugs, accounting for nearly $50 billion in sales in 2009, will go off-patent.

More... »

Quintiles invests $1 million in Prana Biotechnology

Tuesday, July 5, 2011 12:21 PM

Quintiles is raising its stake in Prana Biotechnology, an Australian company focused on Alzheimer’s disease and other major age-related neurodegenerative disorders, by acquiring $1 million worth of new Prana shares, according to PharmaTimes.

More... »

Quintiles invests in Swiss biotech Kareus

Tuesday, June 14, 2011 01:54 PM

In further evidence of a shift toward more fundamental risk-sharing in drug development between biopharmaceutical companies and CROs, Quintiles is making a significant investment in Swiss biotech Kareus Therapeutics as part of a broad strategic alliance to move two of Kareus’ pre-clinical programs through clinical trials, according to PharmaTimes.

More... »

Quintiles’ Chasse, Sanofi Pasteur’s Milam make unprecedented industry move to the site world

Monday, May 23, 2011 08:44 AM

Christine Pierre, president of the investigator site group and consultancy RxTrials, shocked parts of the industry this month when she hired Adam Chasse away from global CRO Quintiles and Dan Milam from Sanofi Pasteur, the largest company in the world devoted to vaccines.

More... »

Quintiles collaborates with PGT

Tuesday, May 17, 2011 11:32 AM

Quintiles has partnered with Population Genetics Technologies (PGT), a U.K.-based company that specializes in large-scale, lower-cost genomic analyses, according to PharmaTimes.

More... »